Emord takes on FDA over supplement GMPs
This article was originally published in The Tan Sheet
Executive Summary
The final rule for dietary supplement good manufacturing practices is "poorly written and unnecessarily a trap for the unwary," asserts attorney Jonathan Emord in a 1complaint filed Aug. 7 against FDA. The GMPs violate the Dietary Supplement Health and Education Act by allowing the agency to hold products as adulterated without proving they present a public health risk, he says. Emord also claims that because firms are not given proper guidance for complying with GMPs, the rule violates the constitutional prohibition against vague laws. Like his July 30 suit regarding FDA's rejection of health claims, the Aug. 7 suit also was filed in the U.S. District Court for the District of Columbia and on behalf of the Alliance for Natural Health U.S., the Coalition to End FDA and FTC Censorship and supplement businesspersons Durk Pearson and Sandy Shaw (2"The Tan Sheet" Aug. 3, 2009, In Brief)
You may also be interested in...
FDA Has Authority To Be Vague On Supplement GMP Standards, Court Rules
FDA can set somewhat vague standards for dietary supplement firms' compliance with some good manufacturing practice regulations, according to a ruling in a complaint challenging the agency's authority to issue GMP requirements.
Suit claims FDA "censorship" on QHCs
FDA's rejection of certain qualified health claims linking selenium to cancer prevention violates a federal court ruling that mandates a First Amendment standard for reviewing QHCs, Jonathan Emord asserts. The Clifton, Va.-based attorney filed a 1complaint July 30 in the U.S. District Court for the District of Columbia on behalf of the Alliance for Natural Health U.S., the Coalition to End FDA and FTC Censorship, which Emord founded, and supplement businesspersons Durk Pearson and Sandy Shaw. FDA recently approved a number of narrowly qualified, essentially unusable QHCs for selenium in response to an Emord citizen petition (2"The Tan Sheet" June 29, 2009). "FDA has denied consumers accurate representations of nutrition science," the complaint states
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.